Orexo Ab (ORXOY) 19.8700 $ORXOY
Orexo signs exclusive reimbursement agreement for ZUBSOLV with UnitedHealth Group and OptumRx
M2 - Wed Mar 12, 8:24AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the signing of a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV.
Orexo closes on new SEK200m revolving credit facility
M2 - Thu Dec 12, 6:47AM CST
Orexo AB (STO: ORX.ST), a specialty pharmaceutical company, announced today the closing of a SEK200m revolving credit facility with Danske Bank.
Orexo's Abstral launched in Japan
M2 - Thu Dec 12, 6:42AM CST
Orexo AB (STO:ORX.ST), a specialty pharmaceutical company, announced today the commencement of the Japanese launch of Abstral by Kyowa Hakko Kirin Co Ltd.
Orexo reports change in number of shares and votes in November 2013
M2 - Mon Dec 02, 4:38AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday that there has been a change in its number of shares and votes as a result of the exercise of warrants in connection with the company's incentive programmes.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Orexo's ADRs commence trading on OTCQX in the US
M2 - Thu Nov 14, 4:36AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Wednesday that its sponsored Level 1 American Depositary Receipts (ADRs) commenced trading on OTCQX International, a segment of the OTCQX marketplace in the US, on 13 November 2013, under the symbol 'ORXOY'.
Orexo AB Begins Trading on OTCQX®
PR Newswire - Wed Nov 13, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Orexo AB (OTCQX: ORXOY; OMX Nordic Exchange Stockholm: ORX), an emerging specialty pharmaceuticals company with commercial operations in the U.S. and research and development in Sweden, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX, the best marketplace with qualified companies.
Orexo appoints Nomination Committee for AGM 2014
M2 - Wed Oct 16, 5:16AM CDT
Specialty pharmaceutical company Orexo (STO:ORX.ST)(OTC:ORXOY) on Tuesday appointed its nomination committee, prior to its Annual General Meeting 2014, which represents approximately 49% of the number of shares and votes in the company based on the last known shareholder information.
Orexo receives approval for Abstral in Japan
M2 - Fri Sep 20, 5:00AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday receipt of the approval for Abstral (fentanyl) sublingual tablets in Japan.
/C O R R E C T I O N -- Orexo U.S./
PR Newswire - Mon Sep 16, 9:04AM CDT
In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows:
Orexo signs exclusive reimbursement agreement for ZUBSOLV with UnitedHealth Group and OptumRx
M2 - Wed Mar 12, 8:24AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the signing of a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV.
Orexo closes on new SEK200m revolving credit facility
M2 - Thu Dec 12, 6:47AM CST
Orexo AB (STO: ORX.ST), a specialty pharmaceutical company, announced today the closing of a SEK200m revolving credit facility with Danske Bank.
Orexo's Abstral launched in Japan
M2 - Thu Dec 12, 6:42AM CST
Orexo AB (STO:ORX.ST), a specialty pharmaceutical company, announced today the commencement of the Japanese launch of Abstral by Kyowa Hakko Kirin Co Ltd.
Orexo reports change in number of shares and votes in November 2013
M2 - Mon Dec 02, 4:38AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday that there has been a change in its number of shares and votes as a result of the exercise of warrants in connection with the company's incentive programmes.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Orexo's ADRs commence trading on OTCQX in the US
M2 - Thu Nov 14, 4:36AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Wednesday that its sponsored Level 1 American Depositary Receipts (ADRs) commenced trading on OTCQX International, a segment of the OTCQX marketplace in the US, on 13 November 2013, under the symbol 'ORXOY'.
Orexo AB Begins Trading on OTCQX®
PR Newswire - Wed Nov 13, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Orexo AB (OTCQX: ORXOY; OMX Nordic Exchange Stockholm: ORX), an emerging specialty pharmaceuticals company with commercial operations in the U.S. and research and development in Sweden, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX, the best marketplace with qualified companies.
Orexo appoints Nomination Committee for AGM 2014
M2 - Wed Oct 16, 5:16AM CDT
Specialty pharmaceutical company Orexo (STO:ORX.ST)(OTC:ORXOY) on Tuesday appointed its nomination committee, prior to its Annual General Meeting 2014, which represents approximately 49% of the number of shares and votes in the company based on the last known shareholder information.
Orexo receives approval for Abstral in Japan
M2 - Fri Sep 20, 5:00AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday receipt of the approval for Abstral (fentanyl) sublingual tablets in Japan.
/C O R R E C T I O N -- Orexo U.S./
PR Newswire - Mon Sep 16, 9:04AM CDT
In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows:
